Indaptus Therapeutics, Inc.
INDP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001857044
No open-market purchases or sales by Indaptus Therapeutics, Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $1.15M in total; no superinvestor holds it.
13F holders, Q2 2022
Institutional positions in Indaptus Therapeutics, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 17
- 0 vs. Q1 2022
- Shares held
- 501.1K
- −1.21M (−70.7%) vs. Q1 2022
- Total value
- $1.31M
- −$5.51M (−80.8%) vs. Q1 2022
- New holders
- 4
- 2 more added
- Sold out
- 4
- 3 more reduced
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INDP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 9 | $1.15M |
| Q1 2026 | 6 | $128.5K |
| Q4 2025 | 4 | $93.7K |
| Q3 2025 | 5 | $57.9K |
| Q2 2025 | 5 | $3.23K |
| Q1 2025 | 19 | $377.8K |
| Q4 2024 | 20 | $539.6K |
| Q3 2024 | 18 | $750.3K |
| Q2 2024 | 21 | $1.26M |
| Q1 2024 | 17 | $1.32M |
| Q4 2023 | 19 | $1.06M |
| Q3 2023 | 16 | $1.57M |
| Q2 2023 | 15 | $1.11M |
| Q1 2023 | 15 | $1.08M |
| Q4 2022 | 18 | $838.5K |
| Q3 2022 | 18 | $1.22M |
| Q2 2022 | 17 | $1.31M |
| Q1 2022 | 17 | $6.81M |
| Q4 2021 | 15 | $10.5M |
| Q3 2021 | 15 | $4.24M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding Indaptus Therapeutics, Inc.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 246,947 | $645.0K | 0.00% | +4,712+1.9% | Added |
| Investment House LLC | 95,629 | $250.0K | 0.02% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 52,475 | $136.0K | 0.00% | −60,571−53.6% | Reduced |
| Stratos Wealth Partners, LTD. | 26,832 | $70.0K | 0.00% | −1,161,524−97.7% | Reduced |
| Vivaldi Capital Management, LLC | 24,000 | $63.0K | 0.02% | 00.0% | Unchanged |
| State Street Corp | 19,473 | $51.0K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 19,600 | $51.0K | 0.00% | +19,600 | New |
| Northern Trust Corp | 10,296 | $27.0K | 0.00% | 00.0% | Unchanged |
| Harel Insurance Investments & Financial Services Ltd. | 2,888 | $7.00K | 0.00% | +2,888 | New |
| Tower Research Capital LLC (TRC) | 1,705 | $4.00K | 0.00% | +1,705 | New |
| Morgan Stanley | 542 | $1.00K | 0.00% | −5−0.9% | Reduced |
| National Bank of Canada | 500 | $1.00K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 101 | $0 | 0.00% | +3+3.1% | Added |
| Group One Trading, L.P. | 6 | $0 | 0.00% | 00.0% | Unchanged |
| Captrust Financial Advisors | 13 | $0 | 0.00% | 00.0% | Unchanged |
| Steward Partners Investment Advisory, LLC | 28 | $0 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 19 | $0 | 0.00% | +19 | New |
| United Capital Financial Advisers, LLC | 0 | $0 | 0.00% | −15,000−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −3,294−100.0% | Sold out |
| Cambridge Trust Co | 0 | $0 | 0.00% | −47−100.0% | Sold out |
| Creative Planning | 0 | $0 | 0.00% | −63−100.0% | Sold out |